Please login to the form below

Not currently logged in
Email:
Password:

Pfizer's Wyeth acquisition gets EC go ahead

Pfizer has announced that the EC has cleared its $68bn purchase of Wyeth

Pfizer has announced that the European Commission(EC) (under the European Union Merger Regulation authorisation process) has cleared its $68bn purchase of Wyeth.

"We are pleased to have achieved another significant milestone for the pending acquisition with the EC's approval of the transaction," said Amy Schulman, senior vice president and general counsel of Pfizer.

Pfizer agreed to buy Wyeth in January, but approvals from regulators and governments on several continents are required due to the size of the businesses involved. Pfizer has also said that the Chinese Ministry of Commerce has extended its review of the deal beyond the initial 30 days. Meanwhile, in the US, a 90-day regulatory review continues.

Wyeth shareholders are scheduled to vote on the merger today and the deal is expected to close at the end of the third quarter or during the fourth.

20th July 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Weber Shandwick

At Weber Shandwick, engagement has always been the cornerstone of health communications.We make health matter. Health is a basic human...

Latest intelligence

blood
‘How is your day?’
The initiative that shows how plasma protein therapies improve lives...
women
Advancing women in healthcare
Fostering the next generation of leaders...
The Challenges Of UX In Healthcare: Technology To Change Lives
Blue Latitude Health Director and Head of Customer Experience Elisa Del Galdo explores the latest digital healthcare trends and reveals the innovations changing the sector today....

Infographics